• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Public Health . Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2

tetano

Editor, Senior Moderator
J Infect Public Health


. 2023 Aug 22;16(11):1806-1812.
doi: 10.1016/j.jiph.2023.08.010. Online ahead of print. Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2 variants between January 2020 and April 2022 - A retrospective single-center cohort study

Thomas Theo Brehm[SUP] 1 [/SUP], Andreas Heyer[SUP] 2 [/SUP], Marcel S Woo[SUP] 3 [/SUP], Marlene Fischer[SUP] 4 [/SUP], Marc van der Meirschen[SUP] 2 [/SUP], Dominic Wichmann[SUP] 4 [/SUP], Dominik Jarczak[SUP] 4 [/SUP], Kevin Roedl[SUP] 4 [/SUP], Stefan Schmiedel[SUP] 1 [/SUP], Marylyn M Addo[SUP] 5 [/SUP], Marc Lütgehetmann[SUP] 6 [/SUP], Martin Christner[SUP] 6 [/SUP], Samuel Huber[SUP] 2 [/SUP], Ansgar W Lohse[SUP] 1 [/SUP], Stefan Kluge[SUP] 4 [/SUP], Julian Schulze Zur Wiesch[SUP] 7 [/SUP]



Affiliations
Abstract

Background: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, the roll-out of vaccines and therapeutic agents, as well as the emergence of novel SARS-CoV-2 variants, have shown significant effects on disease severity.
Methods: Patients hospitalized at our center between January 2020 and April 2022 were attributed to subgroups depending on which SARS-CoV-2 variant was predominantly circulating in Germany: (i) Wild-type: January 1, 2020, to March 7, 2021, (ii) Alpha variant: August 3, 2021, to June 27, 2021, (iii) Delta variant: June 28, 2021, to December 26, 2021, and (iv) Omicron variant: December 27, 2021, to April 30, 2022.
Results: Between January 2020 and April 2022, 1500 patients with SARS-CoV-2 infections were admitted to the University Medical Center Hamburg-Eppendorf. The rate of patients who were admitted to the intensive care unit (ICU) decreased from 31.2% (n = 223) in the wild-type group, 28.5% (n = 72) in the Alpha variant group, 18.8% (n = 67) in the Delta variant group, and 13.4% (n = 135) in the Omicron variant group. Also, in-hospital mortality decreased from 20.6% (n = 111) in the wild-type group, 17.5% (n = 30) in the Alpha variant group, 16.8% (n = 33) in the Delta variant group, and 6.6% (n = 39) in the Omicron variant group. The median duration of hospitalization was similar in all subgroups and ranged between 11 and 15 days throughout the pandemic.
Conclusions: In-hospital mortality and rate of ICU admission among hospitalized COVID-19 patients steadily decreased throughout the pandemic. However, the practically unchanged duration of hospitalization demonstrates the persistent burden of COVID-19 on the healthcare system.

Keywords: Alpha variant; COVID-19; Delta variant; Mortality; Omicron variant; SARS-CoV-2.

 
Back
Top Bottom